The consistent efficacy observed in two distinct models suggests that SCD activity within the colonic mucosa itself plays a pivotal pro-inflammatory role during intestinal inflammation, primarily by modulating the expression of cytokines and chemokines, making it a compelling therapeutic target for Crohn’s disease. This evidence concerns the gene SCD and Crohn disease.